Automated insulin delivery University Hospitals NHS Foundation Trust, Wolfson Diabetes and Auutomated Clinic, Depivery, UK. FDA status: No application submitted at present. The in silico false discovery rate was Related Article About the Division.

Automated insulin delivery -

Although the use of new technology has been proven to be beneficial in clinical trials, participation in such trials has so far lacked the necessary diversity across ethnicity, socioeconomic status, and health literacy. One explanation for this may be that research has largely been conducted through academic medical centers, posing a barrier to participants who are unable to travel to these centers partly due to social determinants of health.

The importance of including minorities in clinical studies, beyond the generalizability of outcomes, is contribution to device development along with improved propagation and marketing policies to increase AID use among underrepresented groups In and , the FDA published guidelines on how to enhance population diversity in clinical trials.

Still, there is a need to create regulation and reporting procedures that will promote inclusion and diversity in clinical trials in addition to multidisciplinary stakeholder engagement in disparities research Inequalities in technology access have not been overcome, and the reasons for this beyond the socioeconomic status are poorly understood , Unfortunately, many healthcare systems make access to diabetes technologies in general, and AID systems in particular, very difficult to obtain and maintain.

Advocacy efforts are required to make diabetes technology and AID systems available to all people with diabetes who would benefit from their use. Failure to achieve equity and access to AID systems may translate into a 2-tiered system of diabetes care based on who can, and cannot, access diabetes technology.

Moving forward, to support access to AID systems, all clinicians working with PwD will have to become familiar with the available systems.

Appropriate education should be developed that is high in quality, efficient, and accessible. Coordination and cooperation across professional organizations should be encouraged to maximize impact and reach.

Shared professional resources should be encouraged. Greater coordination, cooperation, and partnership will be the key to providing adequate support and equip clinicians with the required skills so they may confidently offer their patients the best diabetes technologies available, including AID systems.

It is clear that this technology has brought positive life-changing experiences for many users. There are several directions for the future development of the next generation of AID systems:. In December , the FDA authorized the first interoperable AID controller Regulatory agencies across the world are reviewing this issue and we are confident that positive steps will be taken.

Nevertheless, challenges will remain; thus, academic and corporate groups should continue working on a global interoperability standard. The delay associated with insulin absorption from the subcutaneous insulin depot into the bloodstream is still a bottleneck.

Insulin analogs that are absorbed faster are becoming increasingly available , and it is assumed that faster insulin will contribute to better glucose control. However, several studies of insulin delivery via insulin pump or AID found that this assumption is not necessarily accurate in terms of TIR; ultra-rapid insulin provides a modest advantage over rapid insulin analogs, at best, or no advantage , Future studies will show whether proper adaptation of the AID control algorithms to ultra-rapid insulin will result in clinically significant changes.

Alternative routes of insulin delivery are being explored to improve postprandial glycemic control, and initial results are promising, reporting on intraperitoneal IP insulin delivery , or pre-meal inhaled insulin Afrezza when added to an AID system The progress in this direction is directly related to better insulin time-action profiles, alternative routes of insulin delivery, novel control algorithms, and adjunctive agents eg, glucagon, amylin, glucagon-like peptide 1 [GLP-1], and sodium-glucose cotransporter 2 [SGLT-2] therapies.

Additional inputs, such as motion sensing, meal detection, and disturbance anticipation can be employed to control post-meal hyperglycemia and exercise-related hypoglycemia.

Funding agencies are actively supporting research on sensors that could provide additional signals, eg, active insulin, lactate, or ketones, although the utility of these additional signals will still be subject to the pharmacokinetics of subcutaneous insulin delivery.

Multi-hormone closed-loop systems, which include AID plus glucagon 13 , pramlintide 14 or adjuvant medications such as GLP-1 receptor agonists and SGLT-2 inhibitors , to further improve postprandial hyperglycemia, are under investigation.

Of note, the data suggest that the control algorithm in these systems may need to be adaptive to the physiological changes caused by some of these medications, thereby increasing technological complexity and regulatory barriers for multi-hormonal systems.

The size, shape, battery life, physical specifications, and additional customizations of the AID hardware and software will remain critical to system acceptance by the users Convenience and longevity of the infusion sets or tubeless insulin delivery devices must continue to improve—currently, the infusion set is the weakest link in most AID systems.

User burden may be reduced with implanted sensors and combined insulin delivery glucose sensing platforms. And last but not least, AID affordability and reimbursement by health care systems will remain the gateway to system adoption. Cloud databases will play an increasingly important role to support data sharing, virtual clinic visits, and remote access and will allow the deployment of data science tools, such as pattern recognition, neural networks, deep learning, and artificial intelligence.

In silico preclinical trials have been, and will continue to be, used for rapid and cost-effective testing of new ideas Merging large databases with in silico models will create a comprehensive virtual environment for experimenting with new system components prior to their deployment in clinical trials.

Preliminary work showing the potential of adaptation is already published , and a long-term vision for AID personalized medicine strategy has been presented AID key discreet data and the presented consensus report need to be directly integrated into the electronic health record EHR.

This integration is most important for ease of access by clinicians, ease of communication with PwD, and for population health management case management.

Smart insulin pens connected with CGM will enable a kind of AID for people who prefer to use MDI therapy. Given the associated improvements in glycemic control and quality of life measures, clinicians should strongly consider use of AID systems in PwD who would benefit from this technological option.

We recommend that payers support usage of AID systems and other emerging technologies that reduce diabetes burden and improve patient-reported outcomes.

Furthermore, studies have suggested long-term cost saving for health care systems using these systems. Failure to reimburse diabetes technologies such as AID systems will deprive many individuals with T1D who would benefit from this valuable technology and may result in increased disparities in diabetes outcomes due to racial and social inequities , The authors also wish to thank Christopher G Parkin, MS, CGParkin Communications, Inc.

ATTD congress supported the meeting and provided funding to Christopher G. Parkin, CGParkin Communications, Inc. Abbott Diabetes Care, Dexcom, Inc. received Honoraria or consultation fees from Sanofi, Medtronic, Novo Nordisk, Eli Lilly, and Pfizer.

participated in Medical Advisory Board of Sanofi, Medtronic, AstraZeneca, Eli Lilly, Insulet, Pfizer, and Dompe.

is a stock shareholder in NG Solutions Ltd. reports receiving grants from Helmsley Charitable Trust, Dexcom, Medtronic, Abbott Diabetes Care, and Insulet; personal fees and other from DreaMed Diabetes Ltd; personal fees from Novo Nordisk and Eli Lilly; R. owns DreaMed Diabetes Ltd stock.

received Research support from Dexcom, Novo Nordisk, and BD; speaker honoraria from Roche, Lifescan; is an ad board member for Sanofi, Roche. has received research support, has acted as a consultant, or has been on the scientific advisory board for Abbott Diabetes Care, DexCom, Eli Lilly, Insulet, Medtronic, Novo Nordisk, and Sanofi.

served as a consultant for Ascensia, Bigfoot Biomedical, Inc. received research support and speaker honoraria from AstraZeneca, Boehringer, DexCom, Insulet, Lilly, Medtronic, Novo Nordisk, Roche, and Sanofi, and is a shareholder of DreaMed-Diabetes Ltd.

is a speaker for Eli Lilly, Dexcom, and Novo Nordisk; Advisory Board: Eli Lilly; License and consultancy honoraria: B. Braun and Abbott Diabetes Care; Patents related to closed-loop; Director: CamDiab; Research support: Dexcom, Abbott Diabetes Care, Medtronic.

has received consulting fees from Abbott Diabetes Care, CeQur, Dexcom, Mannkind, and Provention. declares that no conflict interest exists. is on the advisory board for Medtronic and Novo Nordisk, speaker at educational symposia sponsored by Novo Nordisk and Sanofi.

Co-investigator on EU IMI HypoRESOLVE program. received research support from Dexcom. reports no personal financial disclosures but reports that his institution has received funding on his behalf as follows: grant funding and study supplies from Tandem Diabetes Care, Beta Bionics, and Dexcom; study supplies from Medtronic, Ascencia, and Roche; consulting fees and study supplies from Eli Lilly and Novo Nordisk; and consulting fees from Insulet, Bigfoot Biomedical, vTv Therapeutics, and Diasome.

has served on Advisory Board Medtronic, Freelancer Diaexpert, Freelancer Medicolab. declares Advisory board for Cardinal Health and Provention Bio; Consultant for WellDoc, Inc; Independent Contractor pump trainer for Insulet and Tandem.

is a speaker and received advisory board fees from Abbott, AstraZeneca, Eli Lilly, Novartis, Roche, Sanofi; noneconomic support from Medtronic. declares Consultant for CamDiab. receives research support from Tandem Diabetes, Dexcom, Novo Nordisk, and Arecor paid to his institution.

serves as a consultant for Dexcom, Adocia, Air Liquide, and Roche. received speaker fees from Tandem and Arecor. reports institutional grants and material funding from Dexcom, Insulet, NIH, Roche Diagnostics, UVA Strategic Investment Fund, Tandem Diabetes Care, and Tolerion.

is a member of advisory board for Medtronic, Convatec, and Arecor. Received consulting fees from Insulet and Medtronic. Received grants support from Insulet, Medtronic, Beta Bionics, JDRF, and NIDDK.

is an employee for Biolinq Inc. has received research support, has acted as a consultant, or has been on the scientific advisory board for Abbott Diabetes Care, DexCom, Eli Lilly, Insulet, Medtronic, Novo Nordisk, Sanofi, Senseionics, and UnitedHealth.

holds stock in Pacific Diabetes Technologies, a company that may have a commercial interest in closed-loop technologies. has been on advisory boards for Novo Nordisk, Astra Zeneca, and Zealand.

received personal fees from Medtronic, Abbott, Dexcom, Insulet, Roche, Sanofi, Lilly, Novo Nordisk, and Astra Zeneca; research support from Novo Nordisk, Sanofi, Abbott, and Medtronic. received grant support diaTribe from Abbott, Ascencia, Bigfoot Biomedical, Dexcom, Insulet, LifeScan, Lilly, Medtronic, Novo Nordisk, One Drop, Roche, Sanofi, Senseonics, Xeris, and Zealand; news service subscription revenue Close Concerns from Abbott, Agamatrix, Air Liquide, Ascencia, BD, Beta Bionics, Bigfoot Biomedical, Biolinq, Capillary Biomedical, Cecilia Health, Cequr, DarioHealth, Dexcom, DreamED Diabetes, Glooko, Insulet, LifeScan, Lilly, MannKind, Medtronic, Metronom, Modular Medical, Novo Nordisk, Onduo, One Drop, Roche, Sanofi, Senseonics, Tandem, Xeris, Ypsomed, and Zealand; diaTribe.

has received research support from Abbott Diabetes Care, DexCom, Insulet, Medtronic, Sanofi, and has been on the scientific advisory board for Insulet. received speaker honoraria from Lilly paid to Institution.

received research support from Medtronic, Dexcom, Novo Nordisk. received research support from Insulet. is a consultant for Dexcom, Insulet.

is a member of EU EXPAMED Panel for Medical products; received speaker honoraria from: Pfizer, Novo Nordisk, and Eli Lilly. received consulting fee from Tandem Diabetes Care and Ypsomed.

received research support from Medtronic, Dexcom, Abbott, Tandem, Insulet, Beta Bionics, and Lilly. Consultant, speaker, advisory board for Medtronic, Dexcom, Abbott, Tandem, Insulet, Beta Bionics and Lilly.

has received Advisory Boards Consulting fee through University of Colorado Denver from Medtronic, Zealand, and Eli Lilly. Research grants through University of Colorado Denver from Eli Lilly, Novo Nordisk, Medtronic, T1D Exchange, NIDDK, JDRF, Dexcom.

No stocks in any device or pharmaceutical company. participates in clinical research or has served as a consultant for: Abbott Diabetes Care, Dexcom, and Medtronic. is the head of HFS-Global LLC which licenses use of Fear of Hypoglycemia Surveys under a partnership with the University of Virginia.

is a member of Medtronic advisory board, a director of Ask Diabetes Ltd providing training and research support in health care settings and received training honoraria from Medtronic, Dexcom, and Sanofi and consulting fees for CamDiab. is a consultant for a number of companies, one of the owners of Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany.

is a speaker for Novo Nordisk, Advisory Boards for Eli Lilly, Novo Nordisk, Zealand, and Zucara. Received research support from Dexcom.

received Research grants from Medtronic Diabetes, Insulet, Beta Bionics; Consulting fee from Abbott Diabetes Care, Roche, Bigfoot, GWave. received consultant fees from Insulet, Cecelia Health, Lifescan Diabetes Institute. declares Consultant to: Dexcom, Eli Lilly, Eoflow, Fractyl, Integrity, Lifecare, Roche Diagnostics, Thirdwayv.

received research support and speaker honoraria from Amgen, B. Braun, Diamyd Medical, Medtronic, Novo Nordisk, Sanofi and is a shareholder of DreaMed Diabetes Ltd. declares Consultant for Abbott Diabetes Care, BioLinq, Capillary Biomedical, Deep Valley Labs, Morgan Stanley, Provention Bio and Tidepool.

is on the advisory board for Abbott Diabetes Care, Dexcom, Insulet, Medtronic, Novo Nordisk, and Sanofi Diabetes Care. declares Speaker: Dexcom, Roche, and Novo Nordisk; Advisory Board: Medtronic. Research support: Dexcom, Abbott Diabetes Care, and Medtronic.

Advisory Board for Medtronic, Abbott Diabetes Care, and Novo Nordisk and research support via institution from Dexcom, Medtronic, Novo Nordisk, and Zealand Pharma. declares Advisory boards and received research support and honoraria from Medtronic, Merck, Novo Nordisk, Sanofi, and Abbott.

declares Advisory boards for Dexcom, Cecelia Health, DiabetesWise. and Tandem. Speaker: Sanofi, NovoNordisk, Eli -Lilly, and Insulet. Received research support: Beta Bionics, Novo Nordisk, Zealand. Patents and patents pending assigned to MGH and licensed to: Beta Bionics.

Honoraria and travel support: Novo Nordisk, Roche, Senseonics. Scientific advisory board: Unomedical, Companion Medical. Speaker: Dexcom, Insulet. Grants: Dexcom, Insulet, Eli Lilly, Novo Nordisk, and Sanofi. Advisory board member for Bigfoot Biomedical, Cecelia Health, Insulet, Medtronic, the T1D Fund, and Vertex.

Research support from Dexcom, Insulet, and Medtronic. Grants: Abbott. Speaker for Abbott, Dexcom, Insulet, Medtronic, and Tandem. Research support to Institution from Abbott. served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic, Indigo, DreaMed Diabetes.

owns stocks of DreamMed Diabetes. Foster NC , Beck RW , Miller KM , et al. State of type 1 diabetes management and outcomes from the T1D Exchange in — Diabetes Technol Ther.

Google Scholar. Brown SA , Kovatchev BP , Raghinaru D , et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. Isganaitis E , Raghinaru D , Ambler-Osborn L , et al.

Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the international diabetes closed-loop trial. McAuley SA , Lee MH , Paldus B , et al. Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial.

Diabetes Care. Collyns OJ , Meier RA , Betts ZL , et al. Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes.

Tauschmann M , Thabit H , Bally L , et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, week randomised trial.

Pease A , Zomer E , Liew D , et al. Cost-effectiveness analysis of a hybrid closed-loop system versus multiple daily injections and capillary glucose testing for adults with type 1 diabetes. Jendle J , Pöhlmann J , de Portu S , Smith-Palmer J , Roze S. Cost-effectiveness analysis of the MiniMed G hybrid closed-loop system versus continuous subcutaneous insulin infusion for treatment of type 1 diabetes.

Bott OJ , Hoffmann I , Bergmann J , et al. HIS modelling and simulation based cost-benefit analysis of a telemedical system for closed-loop diabetes therapy. Int J Med Inform.

Serné EH , Roze S , Buompensiere MI , Valentine WJ , De Portu S , de Valk HW. Cost-effectiveness of hybrid closed loop insulin pumps versus multiple daily injections plus intermittently scanned glucose monitoring in people with type 1 diabetes in The Netherlands.

Adv Ther. Boyne MS , Silver DM , Kaplan J , Saudek CD. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Slattery D , Amiel SA , Choudhary P. Optimal prandial timing of bolus insulin in diabetes management: a review.

Diabet Med. Castellanos LE , Balliro CA , Sherwood JS , et al. Performance of the insulin-only iLet bionic pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting. Haidar A , Tsoukas MA , Bernier-Twardy S , et al. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial.

Youssef J E , Castle J , Ward WK. A review of closed-loop algorithms for glycemic control in the treatment of type 1 diabetes. Forlenza GP , Cameron FM , Ly TT , et al. Fully closed-loop multiple model probabilistic predictive controller artificial pancreas performance in adolescents and adults in a supervised hotel setting.

Bergenstal RM , Garg S , Weinzimer SA , et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. Forlenza GP , Pinhas-Hamiel O , Liljenquist DR , et al. Safety evaluation of the MiniMed g system in children years of age with type 1 diabetes. Brown SA , Beck RW , Raghinaru D , et al.

Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial. Breton MD , Kanapka LG , Beck RW , et al. A randomized trial of closed-loop control in children with type 1 diabetes.

Brown SA , Forlenza GP , Bode BW , et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Carlson AL , Sherr JL , Shulman DI , et al.

Bergenstal RM , Nimri R , Beck RW , et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes FLAIR : a multicentre, randomised, crossover trial. Benhamou P-Y , Franc S , Reznik Y , et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a week multicentre, open-label randomised controlled crossover trial.

Lancet Digital Health. Kariyawasam D , Morin C , Casteels K , et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged years: a randomised, controlled, cross-over, non-inferiority trial.

Lancet Digit Health. Blauw H , Onvlee AJ , Klaassen M , van Bon AC , DeVries JH. Fully closed loop glucose control with a bihormonal artificial pancreas in adults with type 1 diabetes: an outpatient, randomized, crossover trial.

Lum JW , Bailey RJ , Barnes-Lomen V , et al. A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system. Ware J , Allen JM , Boughton CK , et al. Randomized trial of closed-loop control in very young children with type 1 diabetes.

Boughton CK , Hartnell S , Thabit H , et al. Hybrid closed-loop glucose control with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.

Lancet Healthy Longevity. Garg SK , Weinzimer SA , Tamborlane WV , et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes.

Forlenza GP , Ekhlaspour L , DiMeglio LA , et al. Pediatr Diabetes. Sherr JL , Bode BW , Forlenza GP , et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. Schoelwer MJ , Kanapka LG , et al.

Ekhlaspour L , Town M , Raghinaru D , Lum JW , Brown SA , Buckingham BA. Glycemic outcomes in baseline hemoglobin A1C subgroups in the international diabetes closed-loop trial. Online ahead of print. Breton MDS , Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus.

Stone MP , Agrawal P , Chen X , et al. Retrospective analysis of 3-month real-world glucose data after the MiniMed G system commercial launch. Akturk HK , Giordano D , Champakanath A , et al. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes.

Diabetes Obes Metab. Beato-Víbora PI , Gallego-Gamero F , Ambrojo-López A , Gil-Poch E , Martín-Romo I , Arroyo-Díez FJ. Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. Da Silva J , Lepore G , Battelino T , et al.

Real-world performance of the MiniMed G system: first Report of outcomes from Users. Messer LH , Berget C , Pyle L , et al. Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. Hood , KK , Garcia-Willingham N , Hanes S , et al.

Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. doi: doi: Cobry EC , Hamburger E , Jaser SS. Impact of the hybrid closed-loop system on sleep and quality of life in youth with type 1 diabetes and their parents. Abraham MB , de Bock M , Smith GJ , et al.

Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial.

JAMA Pediatr. Messer LH , Berget C , Vigers T , et al. Real world hybrid closed-loop discontinuation: predictors and perceptions of youth discontinuing the G system in the first 6 months. Berget C , Messer LH , Vigers T , et al. Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the G system.

Bergenstal RM , Gal RL , Connor CG , et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels.

Ann Intern Med. Ziegler C , Liberman A , Nimri R , et al. Reduced worries of hypoglycaemia, high satisfaction, and increased perceived ease of use after experiencing four nights of MD-logic artificial pancreas at home DREAM4.

J Diabetes Res. Cobry EC , Kanapka LG , Cengiz E , et al. Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control. Bisio A , Brown SA , McFadden R , et al. Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents.

Wheeler BJ , Collyns OJ , Meier RA , et al. Improved technology satisfaction and sleep quality with Medtronic MiniMed Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with type 1 diabetes in a randomized crossover trial. Acta Diabetol. Kudva YC , Laffel LM , Brown SA , et al.

Patient-reported outcomes in a randomized trial of closed-loop control: the pivotal international diabetes closed-loop trial. Cobry EC , Bisio A , Wadwa RP , Breton MD. Improvements in parental sleep, fear of hypoglycemia, and diabetes distress with use of an advanced hybrid closed loop system.

Barnard KD , Wysocki T , Ully V , et al. Closing the loop in adults, children and adolescents with sub-ptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy.

J Diabetes Sci Technol. Tauschmann M , Allen JM , Nagl K , et al. Home use of day-and-night hybrid closed-loop insulin delivery in very young children: a multicenter, 3-week, randomized trial.

Ekhlaspour L , Schoelwer MJ , Forlenza GP , et al. Safety and performance of the Tandem t:slim X2 with control-IQ automated insulin delivery system in toddlers and preschoolers. Salehi P , Roberts AJ , Kim GJ. Efficacy and safety of real-life usage of MiniMed G automode in children with type 1 diabetes less than 7 years old.

Stewart ZA , Wilinska ME , Hartnell S , et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial.

Kumareswaran K , Thabit H , Leelarathna L , et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomized controlled study.

Thabit H , Hartnell S , Allen JM , et al. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. Akturk HK , Agarwal S , Hoffecker L , Shah VN. Inequity in racial-ethnic representation in randomized controlled trials of diabetes technologies in type 1 diabetes: critical need for new standards.

Dovc K , Battelino T. Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes. Expert Opin Drug Deliv.

Sherr JL , Buckingham BA , Forlenza GP , et al. Safety and performance of the Omnipod hybrid closed-loop system in adults, adolescents, and children with type 1 diabetes over 5 days under free-living conditions. Lal RA , Basina M , Maahs DM , et al.

One year clinical experience of the first commercial hybrid closed-loop system. Braune K , O'Donnell S , Cleal B , et al. Real-world use of Do-It-Yourself artificial pancreas systems in children and adolescents with type 1 diabetes: online survey and analysis of self-reported clinical outcomes.

JMIR Mhealth Uhealth. Varimo T , Pulkkinen MA , Hakonen E , et al. First year on commercial hydrid closed-loop system - experience on children and adolescents with type 1 diabetes. Berget C , Akturk HK , Messer LH , et al.

Real world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: identifying a clinical target for hybrid closed loop use. McAuley SA , Trawley S , Vogrin S , et al. Closed-loop insulin delivery versus sensor-augmented pump therapy in older adults with type 1 diabetes ORACL : a randomized, crossover trial.

Fuchs J , Hovorka R. Benefits and challenges of current closed-loop technologies in children and young people with type 1 diabetes.

Front Pediatr. Fuchs J , Allen JM , Boughton CK , et al. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes KidsAP02 study : an open-label, multicentre, multinational, randomised cross-over study protocol.

BMJ Open. Petruzelkova L , Jiranova P , Soupal J , et al. Pre-school and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: a retrospective analysis.

Dovc K , Boughton C , Tauschmann M , et al. Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. Anderson SM , Buckingham BA , Breton MD , et al. Hybrid closed-loop control is safe and effective for people with type 1 diabetes who are at moderate to high risk for hypoglycemia.

Abitbol A , Rabasa-Lhoret R , Messier V , et al. Overnight glucose control with dual- and single-hormone artificial pancreas in type 1 diabetes with hypoglycemia unawareness: a randomized controlled trial. Malone SK , Peleckis AJ , Grunin L , et al.

Characterizing glycemic control and sleep in adults with long-standing type 1 diabetes and hypoglycemia unawareness initiating hybrid closed loop insulin delivery.

Burckhardt MA , Abraham MB , Dart J , et al. Impact of hybrid closed loop therapy on hypoglycemia awareness in individuals with type 1 diabetes and impaired hypoglycemia awareness. Polsky S , Akturk HK. Case series of a hybrid closed-loop system used in pregnancies in clinical practice.

Diabetes Metab Res Rev. Farrington C , Stewart Z , Hovorka R , Murphy H. Farrington C , Stewart ZA , Barnard K , Hovorka R , Murphy HR. Experiences of closed-loop insulin delivery among pregnant women with Type 1 diabetes.

Stewart ZA , Yamamoto JM , Wilinska ME , et al. Adaptability of closed loop during labor, delivery, and postpartum: a secondary analysis of data from two randomized crossover trials in type 1 diabetes pregnancy.

Bally L , Gubler P , Thabit H , et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int. Kaur H , Schneider N , Pyle L , et al.

Efficacy of hybrid closed-loop system in adults with type 1 diabetes and gastroparesis. Boughton CK , Tripyla A , Hartnell S , et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial.

Nat Med. Sherwood JS , Jafri RZ , Balliro CA , et al. Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study.

J Cyst Fibros. Scully KJ , Palani G , Zheng H , Moheet A , Putman MS. American Diabetes Association. Kovatchev BP , Kollar L , Anderson SM , et al. Carlson AL , Bode BW , Brazg RL , et al. June , ; Virtual. Thabit H , Tauschmann M , Allen JM , et al. Home use of an artificial beta cell in type 1 diabetes.

Bisio A , Gonder-Frederick L , McFadden R , et al. The impact of a recently approved automated insulin delivery system on glycemic, sleep, and psychosocial outcomes in older adults with type 1 diabetes: a pilot study. Bally L , Thabit H , Hartnellet S , et al.

Closed-loop insulin delivery for glycemic control in noncritical care. Mulinacci G , Alonso GT , Snell-Bergeon JK , Shah VN. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes.

Kamrath C , Tittel SR , Kapellen TM , et al. Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry.

Lancet Child Adolesc Health. Champakanath A , Akturk HK , Alonso GT , Snell-Bergeon JK , Shah VN. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study.

Shah SC , Malone JI , Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. Buckingham B , Beck RW , Ruedy KJ , et al. Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes.

University of Cambridge. Closed Loop From Onset in Type 1 Diabetes CLOuD. Accessed September 22, Jaeb Center for Health Research. Hybrid Closed Loop. Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes CLVer.

Patton SR , Noser AE , Youngkin EM , Majidi S , Clements MA. Early initiation of diabetes devices relates to improved glycemic control in children with recent-onset type 1 diabetes mellitus. Battelino T , Danne T , Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range.

Kimbell B , Rankin D , Ashcroft NL , et al. What training, support, and resourcing do health professionals need to support people using a closed-loop system? A qualitative interview study with health professionals involved in the closed loop from onset in type 1 diabetes CLOuD trial.

Messer LH. Why expectations will determine the future of artificial pancreas. Boughton CK , Hartnell S , Allen JM , Fuchs J , Hovorka R. Training and support for hybrid closed-loop therapy. Cescon M , DeSalvo DJ , Ly TT , et al. Early detection of infusion set failure during insulin pump therapy in type 1 diabetes.

Boughton CK , Hartnell S , Allen JM , Hovorka R. The importance of prandial insulin bolus timing with hybrid closed-loop systems. Pinsker JE , Harsimran Singh H , Molly McElwee Malloy MM , et al. A virtual training program for the Tandem t:slim X2 insulin pump: implementation and outcomes.

Vigersky RA , Velado K , Zhong A , Agrawal P , Cordero TL. Gómez AM , Henao D , Parra D , et al. Virtual training on the hybrid close loop system in people with type 1 diabetes T1D during the COVID pandemic.

Diabetes Metab Syndr. Petrovski G , Campbell J , Almajali D , Al Khalaf F , Hussain K. Successful initiation of hybrid closed-Loop system using virtual pump training program in a teenager with type 1 diabetes previously treated with multiple daily injections.

Berget C , Thomas SE , Messer LH , et al. A clinical training program for hybrid closed loop therapy in a pediatric diabetes clinic. Messer LH , Berget C , Ernst A , et al. Initiating hybrid closed loop: a program evaluation of an educator-led control-IQ follow-up at a large pediatric clinic.

Levine BJ , Close KL , Dalton D , et al. Enhancing resources for healthcare professionals caring for people on intensive insulin therapy: summary from a national workshop. Diabetes Res Clin Pract. Messer LH , Berget C , Forlenza GP. A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm.

Ekhlaspour L , Tabatabai I , Buckingham B. A review of continuous glucose monitoring data interpretation in the age of automated insulin delivery. Messer LH , Forlenza GP , Sherr JL , et al. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed G system.

Clinical management and pump parameter adjustment of the control-IQ closed-loop control system: results from a 6-month multicenter randomized clinical trial.

Lehmann V , Zueger T , Zeder A , et al. Lower daily carbohydrate intake is associated with improved glycemic control in adults with type 1 diabetes using a hybrid closed-loop system.

Danne T , Nimri R , Battelino T , et al. International consensus on use of continuous glucose monitoring. Holt RIG , DeVries JH , Hess-Fischl A , et al. The management of type 1 diabetes in adults.

A consensus report by the American Diabetes Association ADA and the European Association for the Study of Diabetes EASD. Glycemic targets: standards of medical care in diabetes— Shah VN , Garg SK.

Standardized hybrid closed-loop system reporting. Weissberg-Benchell J , Hessler D , Polonsky WH , Fisher L. Psychosocial impact of the bionic pancreas during summer camp. Weissberg-Benchell J , Hessler D , Fisher L , Russell SJ , Polonsky WH. Impact of an automated bihormonal delivery system on psychosocial outcomes in adults with type 1 diabetes.

Lawton J , Blackburn M , Rankin D , et al. Gonder-Frederick LA , Grabman JH , Kovatchev B , et al. Is psychological stress a factor for incorporation into future closed-loop systems? Oser SM , Oser TK. Diabetes technologies: we are all in this together. Clinical Diabetes. Barnard-Kelly KD , Chernavsky D.

Social inequalities and diabetes: a commentary. Diabetes Ther. Food and Drug Administration. Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry, April Accessed June 14, Editors, Rubin E.

Striving for diversity in research studies. Flanagin A , Frey T , Christiansen SL , AMA Manual of Style Committee. Updated guidance on the reporting of race and ethnicity in medical and science journals.

Agarwal S , Crespo-Ramos G , Leung SL , et al. Solutions to address inequity in diabetes technology use in type 1 diabetes: results from multidisciplinary stakeholder co-creation workshops. Agarwal S , Kanapka LG , Raymond JK , et al.

Racial-ethnic inequity in young adults with type 1 diabetes. J Clin Endocrinol Metab. Addala A , Auzanneau M , Miller K , et al. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison.

FDA authorizes first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customize their individual diabetes management device system.

Accessed May 4, Svehlikova E , Mursic I , Augustin T , et al. Pharmacokinetics and pharmacodynamics of three different formulations of insulin aspart: a randomized, double-blind, crossover study in men with type 1 diabetes. Dovc K , Piona C , Yeşiltepe Mutlu G , et al.

Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study.

Dassau E , Renard E , Place J , et al. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.

Presti J L , Galderisi A , Doyle FJ , et al. Intraperitoneal insulin delivery: evidence of a physiological route for artificial pancreas from compartmental modeling. Published online ahead of print February 10, : doi: Galderisi A , Cohen N , Calhoun P , et al.

Effect of Afrezza on glucose dynamics during HCL treatment. Sherr JL , Patel NS , Michaud CI , et al. Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide.

Biester T , Muller I , von dem Berge T , et al. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: the DAPADream study.

Haidar A , Yale JF , Lovblom LE , et al. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery artificial pancreas and empagliflozin: a randomized, controlled, non-inferiority, crossover pilot trial.

Commissariat PV , Roethke LC , Finnegan JL , et al. Youth and parent preferences for an ideal AP system: it is all about reducing burden. Viceconti M , Cobelli C , Haddad T , Himes A , Kovatchev BP , Palmer M. In silico assessment of biomedical products: the conundrum of rare but not so rare events in two case studies.

Proc Inst Mech Eng H. Messori M , Kropff J , Del Favero S , et al. for the AP home consortium. Individually adaptive artificial pancreas in subjects with type 1 diabetes: a one-month proof-of-concept trial in free-living conditions. Shi D , Dassau E , Doyle FJ III.

Multivariate learning framework for long-term adaptation in the artificial pancreas. Bioeng Transl Med. Lipman TH , Hawkes CP. Racial and socioeconomic disparities in pediatric type 1 diabetes: time for a paradigm shift in approach. Walker AF , Hood KK , Gurka MJ , et al.

Barriers to technology use and endocrinology care for underserved communities with type 1 diabetes. Navbar Search Filter Endocrine Reviews This issue Endocrine Society Journals Clinical Medicine Endocrinology and Diabetes Medicine and Health Books Journals Oxford Academic Mobile Enter search term Search.

Endocrine Society Journals. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Evolution of AID Systems. Summary of Clinical Evidence. Target Populations for AID Therapy. Initiating AID System Use. Education, Training, and Support.

Clinical Recommendations for AID Use. How to Report and Present AID Data. Psychological Issues and PwD Perspectives on AID Systems. The Future of AID: What Will It Look Like? Funding and Duality of Interest. Journal Article. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.

Moshe Phillip , Moshe Phillip. Email: mosheph tauex. Email: revitalnimri gmail. com , Ravitaln clalit. Oxford Academic.

Revital Nimri. Richard M Bergenstal. International Diabetes Center, HealthPartners Institute. Katharine Barnard-Kelly. Southern Health NHS Foundation Trust. Thomas Danne. AUF DER BULT, Diabetes-Center for Children and Adolescents, Endocrinology and General Paediatrics.

Roman Hovorka. Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge. Boris P Kovatchev. Center for Diabetes Technology, School of Medicine, University of Virginia.

Laurel H Messer. Barbara Davis Center for Diabetes, University of Colorado Denver—Anschutz Medical Campus. Christopher G Parkin.

CGParkin Communications, Inc. Louise Ambler-Osborn. Joslin Diabetes Center, Harvard Medical School. However, people of all ages can be diagnosed with type 1 diabetes. This range is widely accepted as the target range by the American Diabetes Association guidelines for a non-pregnant individual.

Learn more about time in range and what it means for someone living with type 1 diabetes. The purpose of an automated insulin delivery system is to help offset some of these factors.

When someone with diabetes goes outside of this target range they may experience hypoglycemia lows or hyperglycemia highs. Learn more about the differences between hypoglycemia and hyperglycemia — including the signs and symptoms of hypoglycemia or hyperglycemia — and what it means for someone living with diabetes.

Today, automated insulin delivery systems are recommended 1 for all people with type 1 diabetes. There are several different options for people with type 1 diabetes who need daily insulin therapy.

One of the most common treatment options is multiple daily injections. This is sometimes called MDI insulin therapy. Similar to MDI therapy, insulin pens require multiple injections throughout the day on an as-needed basis.

Pens typically come with the insulin prefilled to help with dosing. An insulin pump gives a steady release of insulin called a basal rate throughout the day.

It can also deliver a larger dose of insulin, called a bolus, that is initiated by the user prior to meals. When a pump has a CGM and a predictive algorithm, it can form an AID system.

Learn more about insulin and how it works. While type 1 diabetes is an autoimmune disease, type 2 diabetes can develop over time for many reasons, including lifestyle and genetics.

It is most commonly diagnosed in adulthood. Just as there are multiple options for managing type 1 diabetes, there are also several ways to manage type 2 diabetes.

Learn more about the signs and symptoms of type 2 diabetes. Someone living with type 2 diabetes may choose to manage their diabetes with an insulin pump. One of the benefits of an insulin pump is that there likely will be fewer injections. An insulin pump with a predictive algorithm, along with the use of a CGM, could create an automated insulin delivery system for type 2 diabetes.

Tandem Diabetes Care makes the t:slim X2 insulin pump with Control-IQ technology. This predictive algorithm can anticipate glucose levels up to 30 minutes in advance when paired with a CGM sold separately to help prevent highs and lows.

The t:slim X2 insulin pump with Control-IQ technology is the 1 rated automated insulin delivery system and the t:slim X2 is the 1 rated pump. Pinsker explained. Learn more about the t:slim X2 insulin pump with Control-IQ technology. Control-IQ technology does not prevent all highs and lows.

You must still bolus for meals and actively manage your diabetes. References 1. ElSayed NA, Aleppo G, Aroda VR, et al. Diabetes Technology: Standards of Care in Diabetes - Diabetes Care. doi: Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology.

Diabetes Technol Ther. Important Safety Information RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use.

The t:slim X2 pump and Control-IQ technology are indicated for use with NovoLog or Humalog U insulin. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled ACE pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin.

The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals six years of age and greater.

The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use with NovoLog or Humalog U insulin. Control-IQ technology: Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor iCGM, sold separately and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values.

It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.

Inshlin insulin delivery systems are automated or semi-automated systems designed to assist people with insulin-requiring diabetesby automatically adjusting Aufomated delivery in response to Automated insulin delivery glucose Ajtomated. Currently available systems as felivery October can Automated insulin delivery insukin and Automated insulin delivery deliverg of a single hormone— Replenish clean skincare. Other delifery currently inwulin development Maca root for digestion to improve on current systems by adding one or more additional hormones that can be delivered as needed, providing something closer to the endocrine functionality of the pancreas. The endocrine functionality of the pancreas is provided by islet cells which produce the hormones insulin and glucagon. Artificial pancreatic technology mimics the secretion of these hormones into the bloodstream in response to the body's changing blood glucose levels. Maintaining balanced blood sugar levels is crucial to the function of the brain, liver, and kidneys. Automated insulin delivery AID systems are often referred to using the term artificial pancreasbut the term has no precise, universally accepted definition. Thank innsulin for Mental alertness pills nature. You are delivefy a browser version with limited support Automated insulin delivery CSS. To obtain the best experience, we Holistic anticancer approaches you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear.